<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907763</url>
  </required_header>
  <id_info>
    <org_study_id>SOTB07_AST_III_2012</org_study_id>
    <nct_id>NCT01907763</nct_id>
  </id_info>
  <brief_title>Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients</brief_title>
  <official_title>A 12-week, Multi-center, Randomized, Double Blinded, Parallel Group, Placebo-controlled Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of SOTB07 in asthma patients
      by observing changes FEV1 (% predicted) as the primary efficacy endpoint after oral
      administration of SOTB07 200mg, 400mg, placebo for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12-week, Multi-center, Randomized, Double blinded, Parallel group, Placebo-controlled study
      to Assess the Efficacy and Safety of SOTB07 in asthma patients
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 change from the baseline</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in spirometer parameters</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FeNO</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AM/PM PEFR</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diurnal asthma symptom score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of days with experience of nocturnal asthma symptoms</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amount of beta-2 agonist used (puff/day)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of rescue free day</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of asthma control day</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of asthma exacerbation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treatment failure (severe asthma exacerbation)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in asthma control questionaire score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life questionaire for adult korea asthmatics scores</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patient's global self assessment score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual analogue scale for cough score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers (eosinophil, neutrophil, ECP, eotaxin) in blood sample</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers (eosinophil, neutrophil, ECP, eotaxin) in sputum sample</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse Event/ Vital Sign/ Laboratory Test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>SOTB07 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of SOTB07 200mg and One tablet of SOTB 400mg Placebo are administered twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOTB07 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of SOTB07 400mg and One tablet of SOTB 200mg Placebo are administered twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet of SOTB 200mg Placebo and One tablet of SOTB 400mg Placebo are administered twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOTB07 200mg</intervention_name>
    <arm_group_label>SOTB07 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOTB07 400mg</intervention_name>
    <arm_group_label>SOTB07 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOTB 200mg placebo</intervention_name>
    <description>Placebo of SOTB07 200mg</description>
    <arm_group_label>SOTB07 400mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOTB 400mg placebo</intervention_name>
    <description>Placebo of SOTB07 400mg</description>
    <arm_group_label>SOTB07 200mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or eligible female subjects aged 15 years or more

          2. A female is eligible if she is of:

               -  Non-child bearing potential (i.e., physiologically incapable of becoming
                  pregnant), including any female who is at least 2 year after post- menopausal

               -  Child bearing potential and agrees to the acceptable contraceptive methods used
                  consistently and correctly

               -  Negative pregnancy test at screening

          3. Non-smoker for at least 1 year, a pack history of ≤ 10 pack years

          4. Symptom of persistent asthma, as defined by the National Institute of Health (NIH)
             5.50% ≤ FEV1 ≤ 80% predicted at screening visit (withholding inhaled, short acting
             ß-agonist for 6 hours)

        6.FEV1 reversibility ≥ 12% and 200 ml at 20-30 minutes after inhalation of a short acting
        ß-agonist (Salbutamol 2 puffs; 200㎍) at Visit 1 or within 6 months before Visit 1 7.Capable
        of withholding salbutamol use for ≥ 6 hours prior to clinic visits 8.Appropriately signed
        and dated informed consent has been obtained

        Exclusion Criteria:

          1. Active upper or lower respiratory tract infection within 3 weeks before visit 1

          2. Emergency room treatment for asthma within 1 month or hospitalization for asthma
             within 3 months before visit 1

          3. Any evidence of infectious, oncologic, or other active pulmonary disease obtained by
             chest radiography within 12 months before visit 1

          4. Clinically significant, in the opinion of the investigator, hematological, liver,
             renal, heart, neurological disease, or other serious disease

          5. Hypersensitivity to any β2-agonist, sympathomimetic drug, leukotriene receptor
             antagonist or Sophora tonkinensis Radix Rhizoma

          6. Clinically significant and uncontrolled psychiatric disease

          7. history of drug or alcohol abuse

          8. Inhaled, oral or parenteral corticosteroids within 4 weeks before visit 1

          9. Change of Immunotherapy within 6 months before visit 1

         10. Administration of the antiasthma agent within 1 week of visit 1

         11. Administration of any other medication which may affect the course of asthma, or
             interact with sympathomimetic amines

         12. Participation in study using an experimental medication within 1 month before visit 1

         13. Other ineligible subject in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangheon Cho, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>SOTB07</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

